FibroGen Valuation
| FGEN Stock | USD 0.44 0.01 2.33% |
FibroGen is undervalued. FibroGen shows a prevailing Real Value of $2.82 per share. The current price of the firm is $0.44. Our model computes the value of FibroGen from reviewing the firm fundamentals such as Current Valuation of (7.36 M), operating margin of 0.04 %, and Profit Margin of (0.68) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting FibroGen's valuation include:
Price Book 53.8258 | Enterprise Value | Enterprise Value Ebitda (0.17) | Price Sales 0.2459 | Forward PE 61.3497 |
Undervalued
Today
Please note that FibroGen's price fluctuation is dangerous at this time. Calculation of the real value of FibroGen is based on 3 months time horizon. Increasing FibroGen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since FibroGen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of FibroGen Stock. However, FibroGen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.44 | Real 2.82 | Target 10.0 | Hype 0.38 | Naive 0.45 |
The intrinsic value of FibroGen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence FibroGen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of FibroGen helps investors to forecast how FibroGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of FibroGen more accurately as focusing exclusively on FibroGen's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use FibroGen's intrinsic value based on its ongoing forecasts of FibroGen's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against FibroGen's closest peers.
FibroGen Cash |
|
FibroGen Valuation Trend
Knowing FibroGen's actual value is paramount for traders when making sound investment determinations. Using both FibroGen's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
FibroGen Total Value Analysis
FibroGen is currently forecasted to have valuation of (7.36 M) with market capitalization of 44.27 M, debt of 170.46 M, and cash on hands of 438.13 M. The negative valuation of FibroGen may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the FibroGen fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(7.36 M) | 44.27 M | 170.46 M | 438.13 M |
FibroGen Investor Information
About 37.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.23. FibroGen had not issued any dividends in recent years. The entity had 1:1 split on the September 8, 2009. Based on the analysis of FibroGen's profitability, liquidity, and operating efficiency, FibroGen is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.FibroGen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. FibroGen has an asset utilization ratio of 34.89 percent. This suggests that the Company is making $0.35 for each dollar of assets. An increasing asset utilization means that FibroGen is more efficient with each dollar of assets it utilizes for everyday operations.FibroGen Ownership Allocation
FibroGen holds a total of 100.77 Million outstanding shares. 30% of FibroGen outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.FibroGen Profitability Analysis
The company reported the previous year's revenue of 147.75 M. Net Loss for the year was (284.23 M) with loss before overhead, payroll, taxes, and interest of (15.16 M).About FibroGen Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of FibroGen. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of FibroGen based exclusively on its fundamental and basic technical indicators. By analyzing FibroGen's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of FibroGen's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of FibroGen. We calculate exposure to FibroGen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of FibroGen's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 148.2 M | 174.1 M | |
| Pretax Profit Margin | (2.23) | (2.12) | |
| Operating Profit Margin | (2.19) | (2.08) | |
| Net Loss | (2.21) | (2.10) | |
| Gross Profit Margin | 0.79 | 0.82 |
FibroGen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 97.3 M | |
| Quarterly Earnings Growth Y O Y | 0.536 | |
| Forward Price Earnings | 61.3497 |
FibroGen Current Valuation Indicators
FibroGen's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final FibroGen's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as FibroGen, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use FibroGen's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes FibroGen's worth.When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share | Quarterly Revenue Growth 0.154 | Return On Assets |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.